Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 17/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943912 | 1.00 | PTGER4 (0.56) | PTGER4PTGER2PTGER3PTGER1ALDH1A1 | |
| SCHEMBL17475054 | 1.00 | PTGER4 (0.56) | PTGER4PTGER2PTGER3PTGER1ALDH1A1 | |
| SCHEMBL4992221 | 0.93 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4992213 | 0.93 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4687816 | 0.89 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4788484 | 0.89 | PTGER4 (0.58) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5658527 | 0.89 | PTGER4 (0.58) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4788122 | 0.86 | PTGER4 (0.79) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4788126 | 0.86 | PTGER4 (0.79) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL19513757 | 0.85 | PTGER4 (0.47) | PTGER4PTGER2PTGER3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3235817-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9676712-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676712-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160031811-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-02-04 | — | — | US | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144584-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1603874-B1 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1603874-B1 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | PTGIS, PTGIR, PTGES | PTGER4 12/4885PTGER2 25/4885PTGER3 29/4885 |
| US-20160031811-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.